BRTX — Biorestorative Therapies Income Statement
0.000.00%
- $11.63m
- $2.53m
- $0.40m
Annual income statement for Biorestorative Therapies, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | 2024 December 31st | |
---|---|---|---|---|---|
Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
Source: | 10-K | 10-K | 10-K | 10-K/A | 10-K |
Standards: | USG | USG | USG | USG | USG |
Status: | Final | Final | Final | Final | Final |
Revenue | |||||
Total Revenue | 0.077 | 0.046 | 0.12 | 0.146 | 0.401 |
Cost of Revenue | |||||
Gross Profit | — | — | — | — | 0.373 |
Selling / General / Administrative Expenses | |||||
Research And Development | |||||
Unusual Expense / Income | |||||
Total Operating Expenses | 7.57 | 42.5 | 18.8 | 15.4 | 12 |
Operating Profit | -7.49 | -42.5 | -18.7 | -15.2 | -11.6 |
Total Net Non Operating Interest Income / Expense | |||||
Total Net Non Operating Interest Income / Expense | |||||
Other Net Non Operating Costs | |||||
Net Income Before Taxes | -11.3 | -44.3 | -18.5 | -10.4 | -8.98 |
Provision for Income Taxes | |||||
Net Income After Taxes | -11.3 | -44.3 | -18.5 | -10.4 | -8.98 |
Net Income Before Extraordinary Items | |||||
Net Income | -11.3 | -44.3 | -18.5 | -10.4 | -8.98 |
Income Available to Common Shareholders Excluding Extraordinary Items | |||||
Income Available to Common Shareholders Including Extraordinary Items | |||||
Diluted Net Income | -11.3 | -44.3 | -18.5 | -10.4 | -8.98 |
Diluted Weighted Average Shares | |||||
Basic EPS Including Extraordinary Items | |||||
Diluted EPS Including Extraordinary Items | |||||
Diluted EPS Excluding Extraordinary Items | |||||
Normalised Income Before Taxes | |||||
Normalised Income After Taxes | |||||
Normalised Income Available to Common Shareholders | |||||
Diluted Normalised EPS | -16.6 | -23.7 | -5.18 | -2.47 | -1.16 |